1 |
BOURBOULIA D, STETLER-STEVENSON W G. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion[J]. Semin Cancer Biol, 2010, 20(3): 161-168.
|
2 |
TAKEHA S, FUJIYAMA Y, BAMBA T, et al. Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect[J]. Jpn J Cancer Res, 1997, 88(1): 72-81.
|
3 |
JOBIN P G, BUTLER G S, OVERALL C M. New intracellular activities of matrix metalloproteinases shine in the moonlight[J]. Biochim Biophys Acta Mol Cell Res, 2017, 1864(11 Pt A): 2043-2055.
|
4 |
EGEBLAD M, WERB Z. New functions for the matrix metalloproteinases in cancer progression[J]. Nat Rev Cancer, 2002, 2(3): 161-174.
|
5 |
HUANG H. Matrix metalloproteinase-9 (MMP-9) as a cancer biomarker and MMP-9 biosensors: recent advances[J]. Sensors (Basel), 2018, 18(10):E3249.
|
6 |
VILEN S T, SALO T, SORSA T, et al. Fluctuating roles of matrix metalloproteinase-9 in oral squamous cell carcinoma[J]. Sci World J, 2013, 2013: 920595.
|
7 |
ROY R, YANG J, MOSES M A. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer[J]. J Clin Oncol, 2009, 27(31): 5287-5297.
|
8 |
SONG G, XU S, ZHANG H, et al. TIMP1 is a prognostic marker for the progression and metastasis of colon cancer through FAK-PI3K/AKT and MAPK pathway[J]. J Exp Clin Cancer Res, 2016, 35(1): 148.
|
9 |
SEO Y S, PARK J J, KIM J H, et al. Usefulness of MMP-9/TIMP-1 in predicting tumor recurrence in patients undergoing curative surgical resection for gastric carcinoma[J]. Dig Dis Sci, 2007, 52(3): 753-759.
|
10 |
ZHANG Y, QIN L, MA X, et al. Coexpression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 as a prognostic biomarker in gastric cancer[J]. Dis Markers, 2020, 2020: 8831466.
|
11 |
ZHANG S, LI L, LIN J Y, et al. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma[J]. World J Gastroenterol, 2003, 9(5): 899-904.
|
12 |
LIAN P L, LIU Z, YANG G Y, et al. Integrin αvβ6 and matrix metalloproteinase 9 correlate with survival in gastric cancer[J].World J Gastroenterol,2016,22(14): 3852-3859.
|
13 |
PUJADA A, WALTER L, PATEL A, et al. Matrix metalloproteinase MMP9 maintains epithelial barrier function and preserves mucosal lining in colitis associated cancer[J]. Oncotarget, 2017, 8(55): 94650-94665.
|
14 |
SCORILAS A, KARAMERIS A, ARNOGIANNAKI N,et al. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients[J]. Br J Cancer, 2001, 84(11): 1488-1496.
|
15 |
KOSKENSALO S, HAGSTRÖM J, LINDER N,et al. Lack of MMP-9 expression is a marker for poor prognosis in Dukes' B colorectal cancer[J]. BMC Clin Pathol, 2012, 12: 24.
|
16 |
SAITO K, TAKEHA S, SHIBA K, et al. Clinicopathologic significance of urokinase receptor- and MMP-9-positive stromal cells in human colorectal cancer: functional multiplicity of matrix degradation on hematogenous metastasis[J]. Int J Cancer, 2000, 86(1): 24-29.
|
17 |
BISWAS M H, DU C, ZHANG C, et al. Protein kinase D1 inhibits cell proliferation through matrix metalloproteinase-2 and matrix metalloproteinase-9 secretion in prostate cancer[J].Cancer Res,2010,70(5): 2095-2104.
|
18 |
ZHANG Z Y, AMOROSA L F, COYLE S M, et al. Proteolytic cleavage of AMPKα and intracellular MMP9 expression are both required for TLR4-mediated mTORC1 activation and HIF-1α expression in leukocytes[J]. J Immunol, 2015, 195(5): 2452-2460.
|
19 |
LÓPEZ-OTÍN C, MATRISIAN L M. Emerging roles of proteases in tumour suppression[J]. Nat Rev Cancer, 2007, 7(10): 800-808.
|
20 |
WALTER L, PUJADA A, BHATNAGAR N, et al. Epithelial derived-matrix metalloproteinase (MMP9) exhibits a novel defensive role of tumor suppressor in colitis associated cancer by activating MMP9-Notch1-ARF-p53 axis[J]. Oncotarget, 2017, 8(1): 364-378.
|
21 |
GARG P, JEPPSSON S, DALMASSO G, et al. Notch1 regulates the effects of matrix metalloproteinase-9 on colitis-associated cancer in mice[J]. Gastroenterology, 2011, 141(4): 1381-1392.
|
22 |
LI L, ZHANG S, LIN H, et al. Relationship of expression unbalance of matrix metalloproteinase and tissue inhibitor of metalloproteinase to invasiveness and metastasis in gastric carcinomas[J].Ai Zheng,2002,21(3): 305-310.
|
23 |
GRÜNWALD B, SCHOEPS B, KRÜGER A. Recognizing the molecular multifunctionality and interactome of TIMP-1[J]. Trends Cell Biol, 2019, 29(1): 6-19.
|
24 |
YOSHIKAWA T, TSUBURAYA A, KOBAYASHI O,et al. Prognostic value of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with gastric cancer[J]. Cancer Lett, 2000, 151(1): 81-86.
|
25 |
SATO H, KIDA Y, MAI M, et al. Expression of genes encoding type Ⅳ collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells[J]. Oncogene, 1992, 7(1): 77-83.
|
26 |
HAMANO Y, ZEISBERG M, SUGIMOTO H, et al. Physiological levels of tumstatin, a fragment of collagen Ⅳ alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin[J]. Cancer Cell, 2003, 3(6): 589-601.
|
27 |
HELJASVAARA R, NYBERG P, LUOSTARINEN J,et al. Generation of biologically active endostatin fragments from human collagen XⅧ by distinct matrix metalloproteases[J]. Exp Cell Res, 2005, 307(2): 292-304.
|
28 |
JACKSON H W, DEFAMIE V, WATERHOUSE P, et al. TIMPs: versatile extracellular regulators in cancer[J]. Nat Rev Cancer, 2017, 17(1): 38-53.
|
29 |
OVERALL C M, KLEIFELD O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy[J]. Nat Rev Cancer, 2006, 6(3): 227-239.
|
30 |
UNSAL KILIC D, UNER A, AKYUREK N, et al. Matrix metalloproteinase-9 expression correlated with tumor response in patients with locally advanced rectal cancer undergoing preoperative chemoradiotherapy[J]. Int J Radiat Oncol Biol Phys, 2007, 67(1): 196-203.
|